Meeting NewsVideo

VIDEO: MONALEESA-7 shows ‘exciting’ results in premenopausal breast cancer

CHICAGO — The MONALEESA-7 trial demonstrated that adding the CDK4/6 inhibitor ribociclib (Kisqali, Novartis) to endocrine therapy improved OS in patients with premenopausal or perimenopausal, metastatic, hormone receptor-positive breast cancer, Aditya Bardia, MD, MPH, medical oncologist at Massachusetts General Hospital Cancer Center and Harvard Medical School, told HemOnc Today at the ASCO Annual Meeting.

“This is the first time where we have a clinically meaningful [and] statistically significant improvement in overall survival in metastatic breast cancer with a CDK4/6 inhibitor,” Bardia said. “We are really excited about these results and look forward to using CDK4/6 inhibitors in patients with premenopausal breast cancer.” – by Alaina Tedesco

 

Disclosure: Bardia reports consulting or advisory roles with Biotheranostics, Genentech/Roche, Immunomedics, Merck, Novartis, Pfizer, Radius Health, Sanofi, Spectrum Pharmaceuticals and Taiho Pharmaceutical; receiving research funding from Biotheranostics, Genentech/Roche, Immunomedics, Merck, Novartis, Pfizer and Radius Health; and travel, accommodations and expenses from Genentech/Roche, Immunomedics, Merck, Novartis, Pfizer, Radius Health, Spectrum Pharmaceuticals and Taiho Pharmaceutical.

 

 

CHICAGO — The MONALEESA-7 trial demonstrated that adding the CDK4/6 inhibitor ribociclib (Kisqali, Novartis) to endocrine therapy improved OS in patients with premenopausal or perimenopausal, metastatic, hormone receptor-positive breast cancer, Aditya Bardia, MD, MPH, medical oncologist at Massachusetts General Hospital Cancer Center and Harvard Medical School, told HemOnc Today at the ASCO Annual Meeting.

“This is the first time where we have a clinically meaningful [and] statistically significant improvement in overall survival in metastatic breast cancer with a CDK4/6 inhibitor,” Bardia said. “We are really excited about these results and look forward to using CDK4/6 inhibitors in patients with premenopausal breast cancer.” – by Alaina Tedesco

 

Disclosure: Bardia reports consulting or advisory roles with Biotheranostics, Genentech/Roche, Immunomedics, Merck, Novartis, Pfizer, Radius Health, Sanofi, Spectrum Pharmaceuticals and Taiho Pharmaceutical; receiving research funding from Biotheranostics, Genentech/Roche, Immunomedics, Merck, Novartis, Pfizer and Radius Health; and travel, accommodations and expenses from Genentech/Roche, Immunomedics, Merck, Novartis, Pfizer, Radius Health, Spectrum Pharmaceuticals and Taiho Pharmaceutical.

 

 

    See more from Discoveries from ASCO: Breast Cancer